Comparison of tumor-informed and tumor-naïve sequencing assays for ctDNA detection in breast cancer.
Date
2023-06-07ICR Author
Author
Santonja, A
Cooper, WN
Eldridge, MD
Edwards, PAW
Morris, JA
Edwards, AR
Zhao, H
Heider, K
Couturier, D-L
Vijayaraghavan, A
Mennea, P
Ditter, E-J
Smith, CG
Boursnell, C
Manzano García, R
Rueda, OM
Beddowes, E
Biggs, H
Sammut, S-J
Rosenfeld, N
Caldas, C
Abraham, JE
Gale, D
Type
Journal Article
Metadata
Show full item recordAbstract
Analysis of circulating tumor DNA (ctDNA) to monitor cancer dynamics and detect minimal residual disease has been an area of increasing interest. Multiple methods have been proposed but few studies have compared the performance of different approaches. Here, we compare detection of ctDNA in serial plasma samples from patients with breast cancer using different tumor-informed and tumor-naïve assays designed to detect structural variants (SVs), single nucleotide variants (SNVs), and/or somatic copy-number aberrations, by multiplex PCR, hybrid capture, and different depths of whole-genome sequencing. Our results demonstrate that the ctDNA dynamics and allele fractions (AFs) were highly concordant when analyzing the same patient samples using different assays. Tumor-informed assays showed the highest sensitivity for detection of ctDNA at low concentrations. Hybrid capture sequencing targeting between 1,347 and 7,491 tumor-identified mutations at high depth was the most sensitive assay, detecting ctDNA down to an AF of 0.00024% (2.4 parts per million, ppm). Multiplex PCR targeting 21-47 tumor-identified SVs per patient detected ctDNA down to 0.00047% AF (4.7 ppm) and has potential as a clinical assay.
Collections
Subject
circulating tumor DNA
hybrid capture
liquid biopsy
multiplex PCR
whole-genome sequencing
Humans
Female
Breast Neoplasms
Biomarkers, Tumor
High-Throughput Nucleotide Sequencing
Circulating Tumor DNA
Mutation
Research team
Cancer Dynamics
Language
eng
Date accepted
2023-04-06
License start date
2023-06-07
Citation
EMBO Molecular Medicine, 2023, 15 (6), pp. e16505 -
Publisher
WILEY
Except where otherwise noted, this item's license is described
as
http://creativecommons.org/licenses/by/4.0/
Related items
Showing items related by title, author, creator and subject.
-
Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue.
Litchfield, K; Stanislaw, S; Spain, L; Gallegos, LL; Rowan, A; et al. (CELL PRESS, 2020-05-05)Although thousands of solid tumors have been sequenced to date, a fundamental under-sampling bias is inherent in current methodologies. This is caused by a tissue sample input of fixed dimensions (e.g., 6 mm biopsy), which ... -
Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors.
Roulleaux Dugage, M; Jones, RL; Trent, J; Champiat, S; Dumont, S (FRONTIERS MEDIA SA, 2021-08-20)Gastrointestinal stromal tumors (GISTs) are a subtype of soft tissue sarcoma (STS), and have become a concept of oncogenic addiction and targeted therapies.The large majority of these tumors develop after a mutation in KIT ... -
Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology.
Failmezger, H; Muralidhar, S; Rullan, A; de Andrea, CE; Sahai, E; et al. (AMER ASSOC CANCER RESEARCH, 2020-03-01)Despite the advent of immunotherapy, metastatic melanoma represents an aggressive tumor type with a poor survival outcome. The successful application of immunotherapy requires in-depth understanding of the biological basis ...